---
schema_version: "secwatch.filing_event.v1"
accession: "0001829126-25-009076"
form_type: "8-K"
ticker: "NTHI"
cik: "0001979414"
company_name: "NEONC TECHNOLOGIES HOLDINGS, INC."
filed_at: "2025-11-12T23:59:59+00:00"
generated_at: "2026-05-16T21:45:37.590950+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# NEO100 yields 21% radiographic response & 44% 6mo PFS in recurrent IDH1-mutant gliomas

## Summary
- Radiographic response rate of 21% (5/24) in recurrent Grade III/IV IDH1-mutant astrocytoma, exceeding <8% benchmark for salvage therapies.
- Six-month progression-free survival (PFS-6) of 44% (8/18 evaluable) vs historical 21-31%.
- 33% of patients (8/24) alive ≥18 months post-NEO100 initiation; median overall survival 88 months.
- No significant toxicity with chronic intranasal dosing; enrollment completed at 25 patients.
- CEO calls data a potential paradigm shift; company advancing to Phase 2b/3 and global trials.

## SEC filing metadata
- accession: 0001829126-25-009076
- form_type: 8-K
- ticker: NTHI
- cik: 0001979414
- company_name: NEONC TECHNOLOGIES HOLDINGS, INC.
- filed_at: 2025-11-12T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1979414/000182912625009076/0001829126-25-009076-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1979414/000182912625009076/neonctechnologies_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001829126-25-009076
- JSON: https://secwatch.observer/filing/0001829126-25-009076.json
- Plain text: https://secwatch.observer/filing/0001829126-25-009076.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.